NovaBridge Biosciences (NBP) Leases (2019 - 2025)

NovaBridge Biosciences (NBP) has 7 years of Leases data on file, last reported at $2.8 million in Q4 2025.

• Quarterly Leases fell 21.91% year-over-year to $2.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.8 million (down 21.91% YoY) and the FY2025 annual result came in at $2.8 million, down 21.91% from the prior year.
• Leases declined to $2.8 million in Q4 2025 per NBP's latest filing, from $3.0 million in the prior quarter.
• Across five years, Leases topped out at $17.6 billion in Q4 2021 and bottomed at $2.8 million in Q4 2025.
• The 5-year median for Leases is $3.7 million (2024), against an average of $1.4 billion.
• The widest annual swing landed in 2021, when Leases jumped 779415.91%; it then sank 99.95% in 2022.
• Tracing NBP's Leases over 5 years: stood at $17.6 billion in 2021, then slumped by 99.95% to $8.9 million in 2022, then retreated by 27.39% to $6.4 million in 2023, then slumped by 44.18% to $3.6 million in 2024, then decreased by 21.91% to $2.8 million in 2025.
• Per Business Quant, the three latest NBP Leases figures stand at $2.8 million (Q4 2025), $3.0 million (Q3 2025), and $3.2 million (Q2 2025).

Peer Comparison